Factors Associated With Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE)

Advances in Therapy - United States
doi 10.1007/s12325-019-00994-7
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Mirabegron: A Beta-3 Agonist for Overactive Bladder

The Consultant Pharmacist
2014English

Overactive Bladder: Symptom or Syndrome?

BJU International
Urology
2003English

Mirabegron &Ndash; A Selective &Szlig;3-Adrenoreceptor Agonist for the Treatment of Overactive Bladder

Research and Reports in Urology
Urology
2012English

The Effect of Mirabegron, Used for Overactive Bladder Treatment, on Female Sexual Function: A Prospective Controlled Study

BMC Urology
MedicineReproductive MedicineUrology
2018English

Pd26-10 Onabotulinumtoxina Provides Early and Consistent Improvements in Overactive Bladder Symptoms and Quality of Life Outcomes in Patients With Overactive Bladder

Journal of Urology
Urology
2017English

Mirabegron as Adjuvant Treatment for Patients With Interstitial Cystitis/Bladder Pain Syndrome

Canadian Urological Association Journal
Urology
2017English

Perceptions of “Urgency” in Women With Interstitial Cystitis/Bladder Pain Syndrome or Overactive Bladder

Neurourology and Urodynamics
NeurologyUrology
2010English

Practical Aspects of Botulinum Toxin-A Treatment in Patients With Overactive Bladder Syndrome

International Neurourology Journal
NeurologyUrology
2015English

Complementing Clinical Cancer Registry Data With Patient Reported Outcomes: A Feasibility Study on Routine Electronic Patient‐reported Outcome Assessment for the Austrian Myelome Registry

European Journal of Cancer Care
Oncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy